, extracts from the annual report issued few weeks ago.
“Continued preparations to initiate the DurAVR® Transcatheter Heart Valve’s (“THV”) randomized global pivotal study (the “Pivotal Trial”) – request for Investigational Device Exemption (“IDE”) on track for submission to the U.S. Food and Drug Administration (“FDA”) in the first quarter of 2025.”
Next couple of weeks are going to be very interesting.
Not Advice, DYOR
“Continued preparations to initiate the DurAVR® Transcatheter...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.03 |
Change
0.010(0.17%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| $6.00 | $6.16 | $5.80 | $52.24K | 8.792K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 857 | $5.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.45 | 1000 | 1 |
View Market Depth
| Last trade - 15.36pm 20/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |